'2025 Sun Life Hong Kong International Dragon Boat Races' Successfully Concluded in Acclamation
HONG KONG SAR – Media OutReach Newswire – 9 June 2025 – The '2025 Sun Life Hong Kong International Dragon Boat Races', organized by the Hong Kong Tourism Board in collaboration with the Hong Kong China Dragon Boat Association and proudly title-sponsored by Sun Life, saw the city's waterfront come alive over the weekend as a huge crowd came to enjoy the mix of international competition and cultural tradition, along with a range of other fun activities.
Sun Life has 21 teams composed of advisors, employees and partners participate in the 'Sun Life Elite Cup', actively supporting the city's dragon boat racing culture.
The annual event attracted numerous citizens to the East Tsim Sha Tsui promenade over the two days (June 7-8) to witness 19 thrilling races in Victoria Harbour that drew over 190 teams and more than 4,500 paddlers from around the world. Among the races, the new 'Sun Life Elite Cup' saw enthusiastic participation from 21 teams made up of Sun Life's advisors, employees, and partners, underscoring the company's commitment to preserving and promoting dragon boat culture.
ADVERTISEMENT
Demonstrating its strong commitment to the community, Sun Life has proudly sponsored Maggie's Cancer Caring Centre to form the 'Move for Maggie's Dragon Boat Team'. Comprised of cancer patients, survivors, and their loved ones, the team made an impactful debut at this year's 'Sun Life Elite Cup', raising funds to support individuals affected by cancer. Dr. the Hon Leong Che-Hung, GBM, GBS, OBE, JP, Chairman of the Board of Governors at Maggie's Cancer Caring Centre, attended the event to cheer on the inspiring paddlers. Proceeds from the fundraising will enhance the Centre's free support services, while the dragon boat race itself delivers a powerful message of hope and resilience. Through this initiative, participants and supporters alike embrace a positive outlook on living with cancer, inspiring patients and their families to face challenges with renewed courage and hope.
Mr. Clement Lam, Chief Executive Officer of Sun Life Hong Kong Limited, said: 'As an international financial institution rooted in Hong Kong for over 130 years, our 16-year commitment to local dragon boat racing reflects not only our dedication to sustaining cultural heritage, but also our pledge to grow alongside this city. We are proud that Sun Life has helped propel this tradition onto the global stage, embodying the city's spirit of teamwork and energy. Moving forward, we will continue to support diverse sports initiatives, offering innovative experiences that blend athletics, culture, and entertainment for citizens and tourists, ultimately helping our Clients live healthier lives while also creating societal value.'
Alongside the main event, Sun Life launched a variety of engaging promotional activities, both online and offline, that attracted widespread participation across the city. A highlight was the 'Sun Life Dragon Boat House', a giant interactive installation at K11 MUSEA that became a viral sensation. Through its multi-platform campaign, Sun Life helped deepen public appreciation for this cultural tradition – and encouraged greater participation too.
The triumph of the '2025 Sun Life Hong Kong International Dragon Boat Races' reflects the ability of Hong Kong to host world-class events and attract new audiences to an old tradition. It all bodes well for next year.
Hashtag: #SunLife永明 #永明金融 #SunLife #香港國際龍舟邀請賽 #龍舟 #盛事 #盛事之都 #旅發局 #銘琪癌症關顧中心 #HongKongInternationalDragonBoatRaces #dragonboat #megaevent #eventscapital #tourismboard #Maggie'sCanceCaringCentre
ADVERTISEMENT
The issuer is solely responsible for the content of this announcement.
About Sun Life
Sun Life is a leading international financial services organization providing asset management, wealth, insurance and health solutions to individual and institutional Clients. Sun Life has operations in a number of markets worldwide, including Canada, the United States, the United Kingdom, Ireland, Hong Kong, the Philippines, Japan, Indonesia, India, China, Australia, Singapore, Vietnam, Malaysia and Bermuda. As of March 31, 2025, Sun Life had total assets under management of $1.55 trillion. For more information, please visit www.sunlife.com.
Sun Life Financial Inc. trades on the Toronto (TSX), New York (NYSE) and Philippine (PSE) stock exchanges under the ticker symbol SLF. Sun Life Financial Inc. is the holding company of Sun Life Assurance Company of Canada. Sun Life Hong Kong Limited is a wholly-owned subsidiary of Sun Life Assurance Company of Canada.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Arabian Post
09-08-2025
- Arabian Post
HK-listed IVD Medical Invests HK$149M in Ethereum through HashKey Exchange
HONG KONG SAR – Media OutReach Newswire – 9 August 2025 – HashKey Exchange, Hong Kong's largest * licensed virtual asset trading platform, has entered into a strategic partnership with IVD Medical Holdings Limited ( a publicly listed company on the Hong Kong Stock Exchange. The two parties will collaborate to advance enterprise-level digital asset adoption and explore new models for integrating blockchain with industrial capital. IVD Medical has made a pioneering move with a HK$149 million Ethereum purchase via HashKey Exchange. With access to trading and liquidity services provided by HashKey Exchange, IVD Medical is poised to become a pioneering 'Ethereum treasury' among HK-listed companies. This partnership also marks a further step by HashKey Exchange in advancing the compliant adoption and integration of digital assets within traditional industries and Hong Kong's capital markets. Key areas of collaboration include: ADVERTISEMENT Block Trade Execution: Access to highly efficient and cost-effective ETH execution via HashKey OTC. Liquidity Provision: Support for large-scale transactions through HashKey Exchange's global liquidity network. Asset Optimization Initiatives: Explore yield-enhancement opportunities, including ETH staking, restaking, and DeFi yield strategies, in collaboration with HashKey Cloud, the Web3 infrastructure arm of HashKey Group. Randall Chan, VP of HashKey Exchange, commented: 'IVD Medical's forward-looking move into digital assets demonstrates how traditional industries are embracing innovation to drive growth. HashKey Exchange remains committed to the highest standards of compliance, security, and transparency, and we look forward to supporting IVD Medical in building its Ethereum treasury and exploring the tokenization of healthcare assets. Together, we aim to bridge the digital and real economies and contribute to Hong Kong's position as a global hub for financial innovation.' Gary Deng, Chief Strategy Officer of IVD Medical, added: 'We are delighted to partner with HashKey Exchange. The digital economy is the engine of future growth, and traditional industries must actively integrate to stay ahead in this new wave of technological transformation. Through this collaboration, IVD Medical aims to establish itself as a leading Ethereum Treasury player, strengthen its resilience against market volatility, and deliver long-term value to shareholders.' Hashtag: #IVDMedical #HashKeyExchange The issuer is solely responsible for the content of this announcement. About HashKey Exchange HashKey Exchange is setting a new benchmark for virtual asset trading platforms with its commitment to regulatory compliance, fund security, and platform safety. Operated by Hash Blockchain Limited, it is one of the first licensed retail virtual asset exchanges in Hong Kong. The platform is fully regulated by the Securities and Futures Commission (SFC), holding Type 1 (Dealing in Securities) and Type 7 (Providing Automated Trading Services) licenses under the Securities and Futures Ordinance, as well as a virtual asset trading platform license under the Anti-Money Laundering and Counter-Terrorist Financing Ordinance. As the flagship business of HashKey Group, HashKey Exchange offers a one-stop trading platform for both professional and retail investors. The exchange is certified under ISO 27001 (Information Security Management) and ISO 27701 (Privacy Information Management), ensuring the highest standards of operational and data security. In strict compliance with applicable regulations, HashKey Exchange does not provide services to users in Mainland China, the United States, and certain other jurisdictions. * As of August 8, 2025, HashKey Exchange ranks 17th on CoinGecko, making it the highest-ranked licensed virtual asset exchange in Hong Kong.
Arabian Post
01-08-2025
- Arabian Post
Life Sciences on the Chinese Mainland – Vital signs: Diagnosing trends in the life sciences real estate market on the Chinese mainland
HONG KONG SAR – Media OutReach Newswire – 1 August 2025 –Cushman & Wakefield, a leading global real estate services firm, today released itsreport. It is based on in-depth interview surveys we conducted on professionals active in the life sciences sector on the Chinese mainland. The life sciences industry on the Chinese mainland is undergoing a transformative phase, driven by progressive policies, groundbreaking innovations, the emergence of influential life sciences companies, and strategic regional development. This report delves into the latest trends shaping the sector. Policy Landscape – National and Local Catalysts Reforms enacted in 2024-2025 have significantly accelerated sector development. Nationally, China relaxed restrictions on foreign investment in gene and cell therapy and allowed the establishment of wholly foreign-owned hospitals in key cities. Regulatory incentives – such as data protection and marketing exclusivity – have improved market access for innovative drugs. Locally, cities like Beijing, Shanghai, Shenzhen, Guangzhou, and Suzhou are rolling out targeted subsidies, fast-track approvals, and ecosystem-building programmes that directly benefit biotech development. ADVERTISEMENT Recent national policy initiatives on the Chinese mainland Types of policies Detail information Opening to Foreign Investment In 2024, China eased restrictions on foreign investments in stem cell research, gene therapy, and genetic diagnostics within Free Trade Zones (FTZs) like Beijing, Shanghai, Guangdong, and Hainan. Regulatory Incentives The State Council's Circular No. 53 introduced measures such as regulatory data protection and marketing exclusivity for select pharmaceutical products, including orphan and paediatric drugs. Wholly Foreign-Owned Hospitals China now permits the establishment of wholly foreign-owned hospitals in cities like Beijing, Shanghai, and Shenzhen, enhancing healthcare services and encouraging foreign investment. Source: Cushman & Wakefield Research Industry Innovation and Company Growth Chinese life sciences companies are moving beyond generic drug manufacturing toward innovative therapies. Firms like Akeso, BeiGene, Gracell, and Legend Biotech are now global players, leading in CAR-T, bispecific antibodies, and AI-assisted R&D. These companies are not only commercialising cutting-edge treatments but also attracting international investment and licensing agreements, reinforcing the Chinese mainland's global relevance in life sciences. Real Estate Development and Regional Hubs ADVERTISEMENT Innovation hubs such as Suzhou BioBAY, Zhangjiang Hi-Tech Park (Shanghai), and the Bioisland Innovation Centre (Guangdong) are central to regional clustering. These hubs offer end-to-end support, including shared labs, venture capital access, GMP-compliant facilities, and proximity to academic and clinical networks. The rise of second-tier innovation cities like Chengdu and Ningbo further expands growth corridors. The 'R&D + Manufacturing + Service' ecosystem Source: Cushman & Wakefield Research Landlord Perspectives – Evolving Real Estate Models Real estate developers and landlords are adapting to sector-specific requirements through asset-light models, flexible leasing, and high-specification lab and production space. Tier-1 cities face saturation, but central and western regions exhibit healthy demand. Developers are incorporating advanced sustainability and compliance features to meet growing regulatory and ESG expectations, particularly in GMP and cleanroom environments. Digitalisation, environmental policies, and differentiated tenant strategies are shaping performance. Operators now focus on integrated ecosystems with platforms that link tenants to R&D services, policy benefits, and technology partners. Occupier Perspectives – Growth, Innovation, and Challenges Life sciences occupiers are navigating regulatory reform, rising compliance demands, and intensified market competition. Many are localising production and R&D, leveraging regional subsidies, and investing in AI-powered innovation platforms. Occupiers seek flexibility, proximity to talent and infrastructure, and co-located R&D and manufacturing to support accelerated innovation and operational agility. In real estate, demand is strongest for GMP-certified labs, modular production facilities, and shared innovation platforms. Occupiers emphasise location advantages, sustainability certifications (e.g., LEED, WELL), and integration into clusters that enable faster time-to-market. Tony Su, Managing Director, National Head of Industrial & Logistics Property Services, China, said, 'Life sciences business parks on the Chinese mainland demonstrated clear regional differentiation, highlighting opportunities for strategic positioning. While Tier-1 cities saw more moderate performance due to broader macroeconomic factors and abundant supply, core cities in central and western regions recorded healthy occupancy rates, underpinned by strong industrial clustering and increasingly sophisticated ecosystems – contributing to steady growth in asset value.' Johnathan Wei, President, Project & Occupier Services, China, said, 'Several interviewed life sciences companies on the Chinese mainland achieved revenue growth supported by innovative products and favourable policy tailwinds. While overall growth remained modest for many, a select group reported strong performance, highlighting opportunities for differentiation'. Andrew Chan, Managing Director, Head of Valuation & Advisory Services, Greater China, said,' Looking ahead to 2025 and beyond, growth opportunities lie in AI-driven drug discovery, personalised medicine, advanced therapeutics (CGT, RNA), and green-certified facilities. Government policies continue to support innovation through fast-track approvals, rare disease funding, and subsidies aligned with dual-carbon and ESG goals'. Shaun Brodie, Head of Research Content, Greater China, 'Life sciences real estate is shifting from generic parks to specialised, digitally enabled campuses with high compliance and flexibility. Investment strategies increasingly emphasise long-term partnerships, collaborative operating models, and digital infrastructure. Both landlords and occupiers express cautious optimism, with strategic differentiation and regional targeting seen as keys to unlocking future value'. Please click here to download the full report. Hashtag: #Cushman&Wakefield The issuer is solely responsible for the content of this announcement. About Cushman & Wakefield Cushman & Wakefield (NYSE: CWK) is a leading global commercial real estate services firm for property owners and occupiers with approximately 52,000 employees in nearly 400 offices and 60 countries. In Greater China, a network of 23 offices serves local markets across the region. In 2024, the firm reported revenue of $9.4 billion across its core services of Valuation, Consulting, Project & Development Services, Capital Markets, Project & Occupier Services, Industrial & Logistics, Retail, and others. Built around the belief that Better never settles, the firm receives numerous industry and business accolades for its award-winning culture. For additional information, visit or follow us on LinkedIn (
Arabian Post
25-07-2025
- Arabian Post
Shanghai Healthcare M&A Fund Takes Strategic Stake in MicroPort Scientific Corporation
HONG KONG SAR – Media OutReach Newswire – 25 July 2025 – MicroPort Scientific Corporation (Stock Code: 'MicroPort') announced that Shanghai Healthcare M&A Fund ('SHMAF'), a fund managed by SIIC Capital, a subsidiary of SIIC Group, has entered into a share purchase agreement to acquire 135,335,204 shares in MicroPort held by Otsuka Medical Devices Co., Ltd. Through this transaction, SHMAF will become a strategic shareholder in MicroPort, underscoring its role as a state-backed, professionally operated platform that is creating value and empowering, stabilizing, developing, and reshaping leading biopharmaceutical companies in China. As a homegrown Chinese innovator that has grown into a global leader in high-end medical devices, MicroPort serves as an anchor company for the industry. Its stable development is critical to both China's and the global high-end medical device supply chain. This investment reflects SHMAF's capital-driven approach to providing crucial support to domestic anchor companies, ensuring their stability and support growth of their core assets. SHMAF will support MicroPort's growth momentum and high-quality sustainable development with its expansive resources. Introducing a strategic shareholder to drive growth momentum. The transaction brings in a significant strategic shareholder for MicroPort. Leveraging its state-backed resources and industrial expertise, SHMAF will support MicroPort's development needs, core business expansion, and potential strategic mergers and acquisitions to create synergies that bolster the company's ongoing innovation and scale-up its operations. ADVERTISEMENT Optimizing resource allocation to unlock synergistic value. MicroPort has successfully incubated and nurtured multiple listed companies and specialized, highly influential small companies, in the process establishing a unique MicroPort ecosystem. SHMAF will leverage its capital and operational integration expertise to support MicroPort in refining its development strategy, optimizing resource allocation, and unlocking synergistic value—while fully respecting market dynamics and corporate autonomy—to further strengthen its ecosystem and competitive advantages. Enhancing ecosystem to enhance anchor company value. MicroPort's product portfolio spans across ten major verticals, including cardiovascular intervention, rhythm management, orthopaedics, neurovascular intervention, and surgical robotics, making it a core player in the high-end medical device industrial chain. SHMAF's support will not only drive MicroPort's growth, it will also accelerate its consolidation of upstream and downstream companies in Shanghai, attract highly-skilled talent, and facilitate breakthroughs in critical technologies and core components—ultimately enhancing the global competitiveness of China's high-end medical device industry. This transaction marks another significant step in SHMAF's commitment to serving biopharmaceutical anchor companies. Upholding its value investment principles, SHMAF will collaborate with MicroPort's shareholders and management team to leverage the strategic support and industrial synergies its state-backed platform offers. Together, they will reinforce MicroPort's position as China's innovation engine in high-end medical devices and contribute to the advancement of the biopharmaceutical industry. Hashtag: #SIICCapital #MicroPort #SHMAF The issuer is solely responsible for the content of this announcement. About MicroPort Scientific Corporation Founded in 1998 and headquartered in Shanghai's Zhangjiang, MicroPort Scientific Corporation is a leading domestic innovative high-end medical device group. It began by breaking the import monopoly in the cardiovascular stent field, and after 26 years of innovative development, its business has expanded to areas including rhythm management, orthopaedics, cardiovascular intervention, aortic and peripheral vascular intervention, neurovascular intervention, heart valves, surgical robots, and surgical medical devices. By the end of 2024, MicroPort operated in over 20,000 hospitals across 100 countries and regions worldwide, providing more than 600 solutions for patients covering over 200 diseases. MicroPort has incubated 6 A-share and Hong Kong-listed companies, owns 9 specialized and sophisticated SMEs, 4 technology giant enterprises, and 16 national high-tech enterprises, making it an outstanding representative of Shanghai's technological innovation and industrial transformation. About SIIC Capital As the active fund management platform under SIIC Group, since its establishment, SIIC Capital has been based in Shanghai, connected with Hong Kong, and oriented towards the world, actively exploring investment opportunities in strategic emerging industries such as biomedicine and green environmental protection. Through a multi-currency, full-stage fund matrix layout, it deeply serves national strategies and the construction of biomedicine highlands.
